Intelligence Platform

Patents

Browse 29,054 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11603364

Acyl hydrazone derivative compounds for treating disease

Alterity Therapeutics Limited · Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11603519

T-cell receptor

Takeda Pharmaceutical Company Limited · Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11603365

Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2

The Board of Regents of the University of Texas System · Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11602559

HIV-1 Env fusion peptide immunogens and their use

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11603413

Anti-TMPRSS2 antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11602568

Engineered B lymphocytes and compositions having micro-RNA and methods for making and usin

The Regents of the University of California · Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11603542

Compositions and methods of treating amyotrophic lateral sclerosis (ALS)

VOYAGER THERAPEUTICS, INC. · Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11603351

Carboxamides as modulators of sodium channels

Vertex Pharmaceuticals Incorporated · Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11602563

Pharmaceutical compositions comprising meloxicam

AXSOME THERAPEUTICS, INC. · Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11603392

Vault particles having a modified R8 flexible region

The Regents of the University of California · Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11602551

Use of inosine for the treatment of t-reg deficiency

granted patent

US 11602515

Pharmaceutical compositions comprising dimethyl fumarate

Almirall, S.A. · Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11602556

Insulin mimotopes and methods of using the same

The Regents of the University of Colorado, a Body Corporate · Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11598782

Biomarkers and methods for detection of seizures and epilepsy

Cognizance Biomarkers, LLC · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11597773

CD6 antibody for treatment of T-cell mediated diseases or disorders

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11597853

Coatings containing polymer modified enzyme for stable self-cleaning of organic stains

Regents of the University of Minnesota · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11597916

Nicotine degrading enzyme variants

The Board of Regents of the University of Texas System · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11597765

Use of semaphorin-4D binding molecules for the treatment of Rett syndrome

VACCINEX, INC. · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11597727

Inhibitors of integrin alpha 2 beta 1 and methods of use

The Regents of the University of California · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11597748

Peptide having cytoprotective effect against environmental pollutant and use thereof

CAREGEN CO., LTD. · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11597924

Genome editing systems comprising repair-modulating enzyme molecules and methods of their

Editas Medicine, Inc. · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11597749

Peptide compositions and methods of use

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11596694

Compositions and methods for predicting response to NaPi2b-targeted therapy

Mersana Therapeutics, Inc. · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11596696

Combination therapy with an anti-CD25 antibody-drug conjugate

ADC THERAPEUTICS SA · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted